Kingdon Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Kingdon Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-150,000	Closed	-$5.01M	–	190
2014 Q3	$5.01M	Buy	+150,000	New	+$4.66M	0.22%	109
2014 Q2	–	Sell	-200,000	Closed	-$9.24M	–	233
2014 Q1	$9.24M	Sell	200,000 -380,000	-66%	-$22.3M	0.47%	66
2013 Q4	$41.2M	Sell	580,000 -720,000	-55%	-$55.1M	1.89%	5
2013 Q3	$111M	Buy	1,300,000 +475,000	+58%	+$40.3M	5.47%	2
2013 Q2	$64.9M	Buy	+825,000	New	+$43.8M	3.84%	4

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Kingdon Capital Management's AEGR Position: Q3 2014 in Review

Kingdon Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 45,000 shares — an estimated $1.4M sold.

Kingdon Capital Management first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $41.9M in Q3 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

Kingdon Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Kingdon Capital Management sold 45,000 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $1.4M.
Kingdon Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Kingdon Capital Management's Aegerion Pharmaceuticals position peaked at $41.9M in Q3 2013.
131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Kingdon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.